Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + apatinib + TACE for advanced hepatocellular carcinoma
ChiCTR1900027247Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and Rivoceranib in hepatocellular carcinoma (HCC) and liver cancer, sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Objective response rate. Started Nov 2019; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)liver cancer
Beyond the preview
Go deeper on ChiCTR1900027247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027247.